ResMed Inc. vs SoFi Technologies Inc — how do they compare? ResMed Inc. trades at $226.25 (market cap $32.61B), while SoFi Technologies Inc trades at $17.88 (market cap $23.22B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| RMD | SOFI | |
|---|---|---|
Market Cap | $32.61B | $23.22B |
Sector | Health | Financials |
52-Week High | $293.73 | $32.21 |
52-Week Low | $182.82 | $15.15 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
SoFi Technologies (SOFI) trades at $17.82, down 1.66% on the day, with a bullish technical signal from moving averages despite a neutral RSI. The company reported strong Q2 2026 earnings, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75-$4.85 billion. The stock's valuation shows a P/E of 36.69 and P/S of 5.6, reflecting growth expectations. Analyst consensus is a 'Buy' with a $19.50 price target, though institutional sentiment is mixed with recent position adjustments.
The outlook for SOFI is positive, driven by robust member growth, cross-selling success, and expanding fee-based revenue. Key risks include dependence on interest rate trends, competitive pressures in digital banking, and execution challenges in scaling the technology platform. The stock presents an opportunity for growth investors, but volatility may persist amid macroeconomic uncertainties and investor sensitivity to guidance updates.
Trailing returns across standard periods
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →